Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia

Gautam Borthakur, E. Lin, Nitin Jain, Elihu E. Estey, Jorge E. Cortes, Susan O'Brien, Stefan Faderl, Farhad Ravandi, Sherry Pierce, Hagop Kantarjian

Research output: Contribution to journalArticle

41 Scopus citations

Abstract

BACKGROUND: Therapy related secondary acute myelogenous leukemia (AML) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor. The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML. Earlier reports suggested similar outcomes for patients with de novo and secondary AML associated with corebinding factor (CBF) abnormalities. METHODS: A total of 188 patients with CBF AML were analyzed. The frequency of secondary CBF AML was 9%. RESULTS: Patients with secondary CBF AML were found to have significantly worse overall (OS) and event-free survival (EFS) compared with patients with de novo CBF AML. Secondary CBF AML status appeared to have only marginal significance in multivariate analysis. CONCLUSIONS: Matched analysis (by age, Eastern Cooperative Oncology Group performance status, and additional cytogenetic abnormality) indicated worse OS and EFS in patients with secondary CBF AML.

Original languageEnglish (US)
Pages (from-to)3217-3221
Number of pages5
JournalCancer
Volume115
Issue number14
DOIs
StatePublished - 2009

Keywords

  • Acute myelogenous leukemia
  • Core-binding factor
  • Event-free survival
  • Matched analysis
  • Overall survival
  • Therapy-related

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia'. Together they form a unique fingerprint.

  • Cite this

    Borthakur, G., Lin, E., Jain, N., Estey, E. E., Cortes, J. E., O'Brien, S., Faderl, S., Ravandi, F., Pierce, S., & Kantarjian, H. (2009). Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer, 115(14), 3217-3221. https://doi.org/10.1002/cncr.24367